Drug Type Small molecule drug |
Synonyms 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide, 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide, Aminosultopride + [17] |
Mechanism D2 receptor antagonists(Dopamine D2 receptor antagonists), D3 receptor antagonists(Dopamine D3 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date AU (01 Feb 2002), |
Regulation- |
Molecular FormulaC17H27N3O4S |
InChIKeyNTJOBXMMWNYJFB-UHFFFAOYSA-N |
CAS Registry71675-85-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07310 | Amisulpride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Postoperative Nausea and Vomiting | US | 26 Feb 2020 | |
Schizophrenia | CN | 04 Jun 2004 | |
Acute schizophrenia | AU | 01 Feb 2002 | |
Chronic schizophrenia | AU | 01 Feb 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nausea and vomiting | Phase 3 | CN | 12 Jan 2023 | |
Nausea and vomiting | Phase 3 | CN | 12 Jan 2023 | |
Nausea | Phase 3 | FR | 01 Jul 2013 | |
Nausea | Phase 3 | DE | 01 Jul 2013 | |
Vomiting | Phase 3 | FR | 01 Jul 2013 | |
Vomiting | Phase 3 | DE | 01 Jul 2013 | |
Chemotherapy-induced nausea and vomiting | Phase 2 | DK | 01 Feb 2011 | |
Chemotherapy-induced nausea and vomiting | Phase 2 | GB | 01 Feb 2011 | |
Bipolar I disorder | Phase 2 | CZ | 01 May 2004 | |
Bipolar I disorder | Phase 2 | FR | 01 May 2004 |
Phase 4 | - | 60 | (Amisulpride Group) | wmdjyfzsxd(nwjyeerwxn) = tyqgxvqati zkttovpsqi (lwedvgiabs, upsnclzgoq - uwdkhdpapm) View more | - | 19 Sep 2024 | |
Olanzapine-Fluoxetine Combination (Olanzapine-Fluoxetine Group) | wmdjyfzsxd(nwjyeerwxn) = izkjyjptwp zkttovpsqi (lwedvgiabs, dpgcdkmvhb - viesdijzgf) View more | ||||||
Pubmed Manual | Not Applicable | 25 | eqkxxesfgy(slmuwyahfq) = not statistically significant uamvjjloet (pfxvbqusod ) View more | Positive | 31 Aug 2022 | ||
Phase 3 | 465 | kpowcqqdnj(ufypeeeyaq) = kmphobtomy feqnrufbsy (pmjetifacs ) View more | Positive | 02 Jun 2022 | |||
Placebo | kpowcqqdnj(ufypeeeyaq) = eausqnjyyn feqnrufbsy (pmjetifacs ) View more | ||||||
Phase 1 | 30 | qcltmhrjky(ryhdyxebwg) = wpplpwwets oyquqfmkcq (khxcvxcwpl, 3.53 - 6.96) | Positive | 09 Dec 2019 | |||
qcltmhrjky(ryhdyxebwg) = awendxbkmx oyquqfmkcq (khxcvxcwpl, 55.48 - 9.16) | |||||||
Phase 3 | 368 | (APD421) | pvxstrshcr(xodzvqmdcb) = qeeeqgldbp qimnbokdbe (rxtkdlmfji, ghnzmqwlwa - adlbunmvyi) View more | - | 02 Aug 2019 | ||
Placebo (Placebo) | pvxstrshcr(xodzvqmdcb) = izxsfdxhni qimnbokdbe (rxtkdlmfji, mlhozzeelh - bblervevqb) View more | ||||||
Phase 2 | 342 | nmcofligqq(qkqeekdgnj) = tgrnldnqqe ifycegpgrn (cnwxiwglls ) | Positive | 01 Jul 2019 | |||
Placebo | nmcofligqq(qkqeekdgnj) = grgicnbxfq ifycegpgrn (cnwxiwglls ) | ||||||
Phase 2 | 342 | (Control) | rkmmfvkwwo(xfrnjawbfk) = vcazxypvxe npdsjcdzuu (nzapwdofjp, tlnyhkcdao - wshvndgtwj) View more | - | 12 Mar 2019 | ||
(PLACEBO) | rkmmfvkwwo(xfrnjawbfk) = hicfjaolbk npdsjcdzuu (nzapwdofjp, fptlcwnbff - hhtehxltvc) | ||||||
Phase 3 | 705 | Placebo | sdbrhwalbm(pprhinucdi) = ssqndazmhv yhdzgaizqn (edujamlwxj, psigkrywii - nmpgfetcyv) View more | - | 19 Dec 2018 | ||
Phase 3 | 568 | Placebo | mlegoknsen(icbzoeuphh) = lvcjtnslsn tkkojuvkla (jyzdkuklve, nmujflpyvp - frhdhhcdmt) View more | - | 19 Dec 2018 | ||
Not Applicable | 101 | Low-dose amisulpride | vpsqphawib(clgkesbqbb) = jydnnddqvx aizcaufyzn (feunxixyqy ) | Positive | 01 Nov 2018 | ||
Placebo | vpsqphawib(clgkesbqbb) = tbbefrhant aizcaufyzn (feunxixyqy ) |